The effect of oral L-arginine supplementation on improvement of cardiovascular function and pulmonary artery pressure in patients with major and Intermedia beta-thalassemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210220050430N1

Enrollment

Registered

2021-05-07

Start date

2021-05-20

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Betha thalasemia. Beta thalassemia

Interventions

Intervention 1: Intervention group: Give oral vial L-arginine supplement made by iranian bio fermentation company with dose 0.1 gr /kg divided 2 or 3 time for 8 weeks. Intervention 2: Control gro

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Beta thalassemia major Above 15 years Thalassemia intermedia

Exclusion criteria

Exclusion criteria: Pregnancy Diadetes Sever kidney disease Sever liver disease Sever cardiac disease History of taking this supplement

Design outcomes

Primary

Measure	Time frame
Pulmonary hypertension. Timepoint: 2 month. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr .Shahla Ansari damavandi

Iran University of Medical Sciences

maryam.shams2744@gmail.com+98 21 2222 2041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026